Список проголосовавших за комментарий " Gapping up/down: CAT +6%, BIIB +4.5%, HUM +3%, AA +3%, MCD +2% and NVS +2% after earnings, APFH +9% after M&A news. BBY +2%, JPM +1% and WFC +1% after upgrades; ESRX -11%, LMT -3%, PHM -3% and LLY -3% after earnings<p><strong>Gapping up<br/> In reaction to strong earnings/guidance</strong>:</p><ul><li><strong>CATB</strong> +37.3%, <strong>UIS</strong> +16.6%, <strong>MDR</strong> +9.5%, <strong>LLNW</strong> +9.1%, <strong>SVU</strong> +7.8%, <strong>GCI</strong> +7.6%, <strong>CAT</strong> +6.4%, <strong>RDWR</strong> +5.8%, <strong>AKS</strong> +5.5%, <strong>ATI</strong> +5.4%, <strong>MAS</strong> +5.3%, <strong>BIIB</strong> +4.5%, <strong>LXU</strong> +4.1%, <strong>RAD</strong> +3.8%, <strong>HUM</strong> +3.2%, <strong>RRC</strong> +3.2%, <strong>CR</strong> +3.1%, <strong>ICHR</strong> +3%, (also commences public offering of 4,500,000 ordinary shares by selling shareholders), <strong>AA</strong> +3%, <strong>JBLU</strong> +3%, <strong>FNB</strong> +2.5%, <strong>MCD</strong> +2.4%, <strong>NVS</strong> +2.3%, <strong>RE</strong> +2.3%, <strong>DD</strong> +2%, <strong>WNC</strong> +1.9%, <strong>CNC</strong> +1.4%, <strong>GPK</strong> +1.3%, <strong>EAT</strong> +1.2%, <strong>TSN</strong> +1.1%, <strong>VLO</strong> +1%</li></ul><p><strong>M&A news</strong>:</p><ul><li><strong>NORD</strong> +26.5% (to be acquired by by consortium led by Canada Pension Plan Investment Board and Baring Private Equity Asia for $32.50/share)</li><li><strong>APFH</strong> +9.2% (to be acquired by Tyson Foods (TSN) for $40.25/share in cash)</li><li><strong>STRP</strong> +7.4% (Board determines that an unsolicited offer from a 'multi-national telecommunications company' for $104.64/share in stock constitutes a 'Superior Proposal')</li><li><strong>MVC</strong> +4.8% (MVC Capital announced that Equus Total Return (EQS) will acquire MVC's largest portfolio holding U.S. Gas & Electric; Transaction consideration values USG&E at $167.5 mln)</li><li><strong>TSN</strong> +0.9%</li></ul><p><strong>Select EU financial related names showing strength</strong>:</p><ul><li><strong>CS</strong> +2%, <strong>RBS</strong> +1.4%, <strong>SAN</strong> +1.4%, <strong>LYG</strong> +1.2%</li></ul><p><strong>Other news</strong>:</p><ul><li><strong>CATB</strong> +35.3% (announced additional favorable results across multiple functional assessments in the MoveDMD trial)</li><li><strong>CANF</strong> +25.3% (Barzilai Medical Center's Institutional Review Board has approved the Phase III ACRobat trial protocol and patient enrollment for the study)</li><li><strong>CAPR</strong> +16.2% (positive top-line results from a safety and exploratory efficacy analysis of 6 month data from the randomized 12-month Phase I/II HOPE Clinical Trial of CAP-1002)</li><li><strong>QURE</strong> +8.7% (will present data on its technologies to improve gene therapy as a therapeutic approach at the ASGCT on May 12 )</li><li><strong>OPGN</strong> +5.7% (presents prelim results on its Acuitas Rapid Test)</li><li><strong>ZSAN</strong> +4.4% (continued strength)</li><li><strong>PRTK</strong> +3.7% (presents new data from a Phase 1 study on its once-daily oral and IV, broad spectrum investigational antibiotic omadacycline at the ECCMID 2017)</li><li><strong>IMGN</strong> +3.6% (Highbridge Capital discloses passive stake)</li><li><strong>ABEO</strong> +2.9% (announces that updated Phase 1/2 clinical trial data on the EB-101 gene therapy program)</li><li><strong>GALT</strong> +2.5% (received a Decision to Grant for its patent application for «Composition of Novel Carbohydrate Drug for Treatment of Human Diseases.»)</li><li><strong>NVO</strong> +2.1% (in sympathy with NVS), <strong>LOGI</strong> +2% (enters new $250 mln share buyback program)</li><li><strong>CVS</strong> +1.7% (in sympathy with RAD)</li><li><strong>DE</strong> +1.5% (in sympathy with CAT earnings)</li><li><strong>SNY</strong> +1.3% (in sympathy with NVS)</li><li><strong>X</strong> +1.3% (in sympathy with AA and AKS)</li><li><strong>SHPG</strong> +1.3% (in sympathy with NVS)</li><li><strong>NFLX</strong> +1.2% (signs licensing agreement with China's iQiyi, according to The Hollywood Reporter)</li><li><strong>GSK</strong> +1% (in sympathy with NVS)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>IDRA</strong> +5.8% (initiated with a Outperform at Robert W. Baird; tgt $5)</li><li><strong>BBY</strong> +2.6% (upgraded to Buy from Neutral at BofA/Merrill)</li><li><strong>SUN</strong> +1% (upgraded to Neutral from Sell at Citigroup)</li><li><strong>JPM</strong> +0.8% (upgraded to Buyfrom Neutral at Guggenheim)</li><li><strong>WFC</strong> +0.7% (upgraded to Neutral from Sell at Guggenheim)</li><li><strong>AXP</strong> +0.6% (upgraded to Buy from Neutral at Guggenheim)</li></ul><p><strong>Gapping down<br/> In reaction to disappointing earnings/guidance</strong>:</p><ul><li><strong>ESRX</strong> -11.5%, <strong>NGL</strong> -10.6%, (lowers FY17 guidance) <strong>R</strong> -6.7%, <strong>CDNS</strong> -5.9%, <strong>SWFT</strong> -5.3%, <strong>ABX</strong> -3.7%, <strong>LH</strong> -3.2%, <strong>LMT</strong> -3.2%, <strong>PHM</strong> -2.9%, <strong>LLY</strong> -2.7%, <strong>TECK</strong> -2.2%, <strong>CNI</strong> -2.2%, <strong>XRX</strong> -2%, <strong>ERIC</strong> -1.6%, <strong>ZION</strong> -1.1%, <strong>RMBS</strong> -1%, <strong>TROW</strong> -0.9%, <strong>TMUS</strong> -0.8%, <strong>ST</strong> -0.8%</li></ul><p><strong>Select metals/mining stocks trading lower</strong>:</p><ul><li><strong>EGO</strong> -3.1%, <strong>KGC</strong> -1.6%, <strong>AG</strong> -1.5%, <strong>GG</strong> -1.1%, <strong>GDX</strong> -0.9%, <strong>GOLD</strong> -0.7%</li></ul><p><strong>Other news</strong>:</p><ul><li><strong>CTRV</strong> -25.4% (commences an underwritten public offering)</li><li><strong>MBII</strong> -17.7% (proposes common stock public offering)</li><li><strong>KPTI</strong> -3.8% (commences underwritten public offering of $40 mln in shares of common stock)</li><li><strong>PZRX</strong> -2.1% (modest pullback)</li><li><strong>SITE</strong> -2.1% (announces secondary offering of 8,500,000 shares of common stock by selling stockholders)</li><li><strong>WPZ</strong> -2% (reduces quarterly distribution to $0.60/share from $0.85/share)</li><li><strong>OMED</strong> -1.3% (OncoMed Pharma will reduce its workforce by approximately 50%; co will also seek to maximize the value from potential interest in partnering the assets to which it has worldwide rights)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>ORLY</strong> -0.8% (downgraded to Hold from Buy at Deutsche Bank)</li><li><strong>COL</strong> -0.6% (resumed with a Sell at Goldman)</li><li><strong>GE</strong> -0.6% (downgraded to Neutral from Buy at BofA/Merril)</li><li><strong>BHP</strong> -0.5% (downgraded to Sell from Neutral at Goldman)</li></ul>"